TLX1 and acute lymphoblastic leukemia: Some of overlapping genomic features with TLX1/TLX3 rearranged T-ALL, including NUP214-ABL1 (TKIs) and JAK-STAT pathway (ruxolitinib, a JAK-STAT inhibitor), can be targetable and have been incorporated into ongoing clinical trials [148].